We are live on ! Find out more
HRTX icon

Heron Therapeutics

0.2525 USD
-0.0116
4.39%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
0.2500
-0.0025
0.99%
1 day
-4.39%
5 days
-16.67%
1 month
-28.77%
3 months
-18.28%
6 months
-70.12%
Year to date
-79.96%
1 year
-76.18%
5 years
-97.4%
10 years
-98.59%
 

About: Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Employees: 128

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 28.6%
Neutral 71.4%
Negative 0%
Positive
Zacks Investment Research
10 days ago
CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.
CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
Neutral
Seeking Alpha
10 days ago
Heron Therapeutics, Inc. (HRTX) M&A Call Transcript
Heron Therapeutics, Inc. ( HRTX ) M&A Call November 9, 2026 4:30 PM EST Company Participants Joseph Todisco - CEO & Chairman of the Board of Directors Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Leonid Timashev - RBC Capital Markets, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Leszek Sulewski - Oppenheimer & Co. Inc., Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Presentation Operator Good afternoon, and welcome to the CorMedix Therapeutics conference call to discuss today's transaction announcement, whereby CorMedix will acquire substantially all of the assets of Heron Therapeutics.
Heron Therapeutics, Inc. (HRTX) M&A Call Transcript
Positive
Benzinga
11 days ago
CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal
CorMedix Therapeutics (NASDAQ:CRMD) on Monday said it will acquire substantially all assets and assume certain liabilities of Heron Therapeutics, Inc. (NASDAQ:HRTX) in an upfront transaction valued at approximately $222.6 million.
CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal
Neutral
Zacks Investment Research
11 days ago
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.05 per share a year ago.
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
11 days ago
Heron Therapeutics Announces Third Quarter 2026 Financial Results
CARY, N.C., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and nine months ended September 30, 2026 and recent corporate updates.
Heron Therapeutics Announces Third Quarter 2026 Financial Results
Neutral
GlobeNewsWire
11 days ago
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
Adds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common stock Additional consideration of up to $55 million in earn-out payments to Heron tied to calendar year 2028 ZYNRELEF net sales plus a royalty on net sales of certain products above a sales threshold Transaction expected to be immediately accretive to CorMedix earnings and free cash flow, as well as estimated to generate $45-$60 million in near-term total operating cost synergies CorMedix entered into a new senior secured term loan facility with funds managed by Pharmakon Advisors and will draw $75 million of non-dilutive financing to support the transaction Heron to remain a publicly traded company with its credit facility repaid, a significant position in CorMedix common stock and rights to earn-out and royalty payments Transaction expected to close in the first quarter of 2027, subject to regulatory clearance and approval by Heron stockholders and other customary closing conditions CorMedix to host a conference call and webcast today at 4:30 p.m. Eastern Time PARSIPPANY, N.J.
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
Neutral
GlobeNewsWire
25 days ago
Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
CARY, N.C., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, November 9, 2026, at 8:30 a.m. ET to report third quarter financial results and discuss recent business highlights.
Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
Neutral
Seeking Alpha
3 months ago
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates
Negative
MarketBeat
3 months ago
Heron Therapeutics Q2 Earnings Call Highlights
Heron Therapeutics NASDAQ: HRTX reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the comparable prior-year period, while management said sales of its key products came in below its internal expectations.
Heron Therapeutics Q2 Earnings Call Highlights
Price charts implemented using Lightweight Charts™